Chugai Pharmaceutical Co (TSE:4519) Piotroski F-Score: 5 (As of Jul. 14, 2026) — 29% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4519 Chugai Pharmaceutical Co Ltd TSE:4519
96 GF Score
Price 円7,230.00
GF Value 円7,735.19
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co Piotroski F-Score?

Chugai Pharmaceutical Co TSE:4519 -2.15% 96 Piotroski F-Score is 5 as of Jul. 14, 2026, which is 29% below its 10-year median of 7.00. GuruFocus rates TSE:4519 with a GF Score™ of 96/100 and a GF Value™ of 円7,735.19 (Fairly Valued). The stock has 1 warning sign investors should review. Among 979 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks better than 61.08% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Chugai Pharmaceutical Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Chugai Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

TSE:4519' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 7   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Chugai Pharmaceutical Co was 8. The lowest was 4. And the median was 7.

Chugai Pharmaceutical Co  (TSE:4519) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Chugai Pharmaceutical Co Piotroski F-Score Related Terms


Chugai Pharmaceutical Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Chugai Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chugai Pharmaceutical Co Piotroski F-Score Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 4.00 7.00 8.00 4.00

Chugai Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 7.00 4.00 4.00 5.00

TSE:4519 vs LLY, JNJ, ABBV: Piotroski F-Score Comparison

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Piotroski F-Score falls into.


TSE:4519
96GF Score
Chugai Pharmaceutical Co Ltd TSE:4519
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 97155 + 111213 + 128410 + 115418 = 円452,196 Mil.
Cash Flow from Operations was 119407 + 71089 + 129107 + 122040 = 円441,643 Mil.
Revenue was 290005 + 333176 + 346301 + 321747 = 円1,291,229 Mil.
Gross Profit was 201936 + 232937 + 258742 + 228957 = 円922,572 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(2139482 + 2278347 + 2183588 + 2468595 + 2265101) / 5 = 円2267022.6 Mil.
Total Assets at the begining of this year (Mar25) was 円2,139,482 Mil.
Long-Term Debt & Capital Lease Obligation was 円0 Mil.
Total Current Assets was 円1,539,441 Mil.
Total Current Liabilities was 円327,702 Mil.
Net Income was 111860 + 109496 + 91559 + 97234 = 円410,149 Mil.

Revenue was 315911 + 315678 + 302073 + 288459 = 円1,222,121 Mil.
Gross Profit was 227971 + 231460 + 207771 + 200636 = 円867,838 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(1897764 + 2060163 + 2069736 + 2208373 + 2139482) / 5 = 円2075103.6 Mil.
Total Assets at the begining of last year (Mar24) was 円1,897,764 Mil.
Long-Term Debt & Capital Lease Obligation was 円0 Mil.
Total Current Assets was 円1,516,402 Mil.
Total Current Liabilities was 円208,429 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Chugai Pharmaceutical Co's current Net Income (TTM) was 452,196. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Chugai Pharmaceutical Co's current Cash Flow from Operations (TTM) was 441,643. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=452196/2139482
=0.2113577

ROA (Last Year)=Net Income/Total Assets (Mar24)
=410149/1897764
=0.21612224

Chugai Pharmaceutical Co's return on assets of this year was 0.2113577. Chugai Pharmaceutical Co's return on assets of last year was 0.21612224. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Chugai Pharmaceutical Co's current Net Income (TTM) was 452,196. Chugai Pharmaceutical Co's current Cash Flow from Operations (TTM) was 441,643. ==> 441,643 <= 452,196 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0/2267022.6
=0

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/2075103.6
=0

Chugai Pharmaceutical Co's gearing of this year was 0. Chugai Pharmaceutical Co's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=1539441/327702
=4.6976857

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1516402/208429
=7.27538874

Chugai Pharmaceutical Co's current ratio of this year was 4.6976857. Chugai Pharmaceutical Co's current ratio of last year was 7.27538874. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Chugai Pharmaceutical Co's number of shares in issue this year was 1645.772. Chugai Pharmaceutical Co's number of shares in issue last year was 1645.802. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=922572/1291229
=0.71449139

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=867838/1222121
=0.71010808

Chugai Pharmaceutical Co's gross margin of this year was 0.71449139. Chugai Pharmaceutical Co's gross margin of last year was 0.71010808. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1291229/2139482
=0.60352412

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1222121/1897764
=0.64397944

Chugai Pharmaceutical Co's asset turnover of this year was 0.60352412. Chugai Pharmaceutical Co's asset turnover of last year was 0.64397944. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+0+1+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Chugai Pharmaceutical Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Chugai Pharmaceutical Co (TSE:4519) has a Piotroski F-Score of 5 as of Jul. 14, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Chugai Pharmaceutical Co and its competitors. This is 29% below median its historical median of 7.00. Over the past decade, Chugai Pharmaceutical Co's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #381 out of 979 companies in the Drug Manufacturers industry, placing it in the top 38.9%.
Is Chugai Pharmaceutical Co's Piotroski F-Score too high?
Chugai Pharmaceutical Co's current Piotroski F-Score of 5 is 29% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Chugai Pharmaceutical Co's value of 5 is 0% at this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #381 out of 979 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Chugai Pharmaceutical Co has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Piotroski F-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #381 out of 979 companies for Piotroski F-Score. This puts Chugai Pharmaceutical Co in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Chugai Pharmaceutical Co's value of 5 is 0% at this benchmark. Historically, Chugai Pharmaceutical Co's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Chugai Pharmaceutical Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current Piotroski F-Score is 5, which is 29% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (TSE:4519) is currently considered Fairly Valued. The stock's GF Value™ is 円7,735.19, compared to a current price of 円7,230.00 — trading 6.5% below its estimated fair value. The current Piotroski F-Score is 5, which is 29% below median its 10-year median of 7.00 and 0% at the Drug Manufacturers industry median of 5.00. Chugai Pharmaceutical Co's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Chugai Pharmaceutical Co (TSE:4519), the current Piotroski F-Score is 5 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chugai Pharmaceutical Co (TSE:4519) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of 円7,230.00 is trading 6.5% below its estimated GF Value™ of 円7,735.19. GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4519:

  • Piotroski F-Score: 5 (29% below median its 10-year median of 7.00)
  • GF Value™: 円7,735.19 vs. price of 円7,230.00 (6.5% below fair value)
  • GF Score™: 96/100 with 1 warning sign
  • Industry Position: 0% at the Drug Manufacturers median (#381 of 979)

No single metric tells the full story. See the TSE:4519 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
96GF Score

Get the complete analysis for TSE:4519

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円7,230.00
Price
円7,735.19
GF Value